Results 181 to 190 of about 1,957,522 (351)

Studies on the Biochemistry of Tetrahymena

, 1948
G. W. Kidder, Virginia C. Dewey
openalex   +1 more source

Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation

Molecular Oncology, EarlyView.
Patient‐derived xenografts (PDXs) can be improved by implantation of a humanized niche. We tested different biomaterials and approaches, and demonstrate that the combination of an injectable biomaterial for scaffold creation plus an intravenous route for acute myeloid leukemia (AML) xenotransplantation provide the most convenient and robust approach to
Daniel Busa, Zdenka Herudkova, Jan Hyl, Jakub Vlazny, Filip Sokol, Kvetoslava Matulova, Adam Folta, Jakub Hynst, Lucy Vojtova, Leos Kren, Martin Repko, Zdenek Racil, Jiri Mayer, Martin Culen   +13 more
wiley   +1 more source

Intra-Vitam Staining of Tuberculous Guinea-Pigs with Fat-Soluble Dyes: Studies on the Biochemistry and Chemo-Therapy of Tuberculosis. II [PDF]

, 1912
H. J. Corper
openalex   +1 more source

Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer

Molecular Oncology, EarlyView.
This study employed targeted metabolomic profiling to identify 302 distinct metabolites present in platelet‐rich plasma (PRP), revealing aberrant metabolic profiles amongst individuals diagnosed with colorectal cancer (CRC). Compared to carcinoembryonic antigen (CEA) and cancer antigen 19‐9 (CA199), our metabolite panel showed improved sensitivity ...
Zuojian Hu, Fenglin Shen, Yang Liu, Ziqing Zhong, Yongling Chen, Zhiyuan Xia, Cuiju Mo, Hongxiu Yu   +7 more
wiley   +1 more source

Correction: LSD1 is required for euchromatic origin firing and replication timing. [PDF]

Signal Transduct Target Ther
Wang Y, Huang Y, Cheng E, Liu X, Zhang Y, Yang J, Young JTF, Brown GW, Yang X, Shang Y.   +9 more
europepmc   +1 more source

Biochemistry and Physiology of the Cell [PDF]

, 1949
J. N. Davidson
openalex   +1 more source

KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells

Molecular Oncology, EarlyView.
We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock, Lina Benzien, Sandra Lange, Maja Huehns, Alexandra Runge, Catrin Roolf, Anett Sekora, Gudrun Knuebel, Hugo Murua Escobar, Christian Junghanss, Anna Richter   +10 more
wiley   +1 more source

Correction: Relationships between multivitamins, blood biochemistry markers, and BMC and BMD based on RF: A cross-sectional and population-based study of NHANES, 2017-2018. [PDF]

PLoS One
Xu L, Wu M, Zhang Y, Kun H, Xu J.
europepmc   +1 more source

Clinical Biochemistry

, 1939
NULL AUTHOR_ID
openalex   +1 more source

The biochemistry of diabetes [PDF]

Biochemical Journal, 1988
Roy Taylor, Loranne Agius
openaire   +3 more sources